Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

T

Theracos

Status and phase

Completed
Phase 2

Conditions

Diabetes Mellitus Type 2

Treatments

Drug: Placebo capsules to match EGT0001442
Drug: EGT0001442

Study type

Interventional

Funder types

Industry

Identifiers

NCT01029704
THR-1442-C-402

Details and patient eligibility

About

The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes. The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the effect on weight and HbA1c as well as the effect EGT0001442 has on the amount of glucose produced in the body by the urine.

Full description

This was a phase 2 study to evaluate the efficacy of EGT0001442. The study included two segments: Segment 1 was a single center, open labeled, ascending dose study in 4 groups of 5 diabetic subjects per group who received 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days. The subjects were in clinic for the first 3 days for safety and PK evaluation. Segment 2 was a multi-center, double-blind, placebo-controlled parallel group study. One hundred and thirty one subjects in 5 parallel groups of approximately 25 diabetic subjects per group were randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day or placebo once daily for 28 days in an outpatient setting.

Enrollment

151 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female between the ages of 18 and 70 years diagnosed with type 2 diabetes.
  • Body mass index (BMI) between 18 kg/m2 and 37 kg/m2 (inclusive).
  • HbA1c levels between 6.5 and 9.5 (inclusive) where the upper limit of normal for the HbA1c assay is 6.4% or HbA1c levels between 6.2 and 9.5% (inclusive) where the upper limit of normal for the HbA1c assay is 6.1%.
  • Fasting plasma glucose levels between 126 and 270 mg/dL (7 - 15 mmol/L, inclusive) while on diabetic medications.
  • Treatment naïve subjects with HbA1c between 6.5 and 9.5 and fasting plasma glucose between 126 and 270 mg/dL (7 - 15 mmol/L).
  • If taking drugs for diabetes, must be medically able and willing to discontinue diabetic medications for the duration of the study.
  • Female subjects must be surgically sterilized or postmenopausal.

Exclusion criteria

  • Type 1 diabetes or diabetes treated with insulin injection.
  • Insulin therapy or oral antidiabetic medication other than metformin, sitagliptin, saxagliptin, a sulfonylurea or combination of these.
  • Sitting blood pressure above 150/95 mmHg on two evaluations at least 10 minutes apart at screening.
  • Positive results on screen for drugs of abuse.
  • Previous treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.
  • Previous treatment with EGT0001474 or EGT0001442.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

151 participants in 2 patient groups, including a placebo group

EGT0001442
Experimental group
Treatment:
Drug: EGT0001442
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo capsules to match EGT0001442

Trial documents
1

Trial contacts and locations

12

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems